ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET
Rhea-AI Summary
ANI Pharmaceuticals (NASDAQ: ANIP) has scheduled its first quarter 2025 financial results announcement for Friday, May 9, 2025, before market opening. The company will host a conference call at 8:00 a.m. ET to discuss the results.
Key executives participating in the call include President and CEO Nikhil Lalwani, SVP Finance and CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz. Investors can access the call via toll-free number 800-225-9448 using Conference ID 4921902.
The webcast will be available live and for replay on the company's website under the Investors section. A replay option will be accessible for two weeks by calling 800-753-8591 with access code 4921902.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ANIP gained 4.69%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open.
Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows:
| Date | Friday, May 9, 2025 | |
| Time | 8:00 a.m. ET | |
| Toll free (U.S.) | 800-225-9448 | |
| Conference ID | 4921902 | |
| Webcast (live and replay) | www.anipharmaceuticals.com, under the “Investors” section |
A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-753-8591 and entering access code 4921902.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.
Investor Relations Contact:
Lisa M. Wilson, In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com
SOURCE: ANI Pharmaceuticals, Inc.
FAQ
When will ANI Pharmaceuticals (ANIP) release Q1 2025 earnings?
How can investors access ANIP's Q1 2025 earnings call?
Who will be presenting at ANI Pharmaceuticals' Q1 2025 earnings call?
How long will ANIP's Q1 2025 earnings call replay be available?
